FED UP with Bleeding Disorders Act of 2026
- Bill Number
- H.R. 8794
- Origin Chamber
- House
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-05-13: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-06-09T08:05:59Z
AI-Generated Summary
Purpose This legislation aims to increase research, education, and access to care for bleeding disorders, with a focus on women and girls in underserved populations, including those in rural areas.
Key Provisions
- Findings: The bill outlines data on bleeding disorders, noting that up to 1% of U.S. women may be affected, often with diagnosis delays of 16 years or more; it highlights benefits of hemophilia treatment centers, risks in pregnancy, economic costs of heavy menstrual bleeding, and relevance to military blood research.
- Interagency Review (Section 3): The Secretary of Health and Human Services (HHS) leads a review of federal programs on the science of bleeding disorders in women and girls, provider training, treatment access (including at hemophilia treatment centers and in rural areas), and inclusion in clinical research. A comprehensive report is due within two years, covering assessments, recommendations for improvements, and better coordination among agencies such as HHS, CMS, HRSA, CDC, NIH, VA, Defense Health Agency, and FDA. Public comments are required, with input prioritized from affected individuals, advocacy groups, and funded researchers.
- National Education Campaign (Section 4): Within one year of the report, HHS awards grants or contracts for an evidence-based nationwide awareness effort targeting women, girls, and providers (e.g., obstetricians, hematologists, school nurses). It must use culturally appropriate materials, reach rural areas, and include dissemination to health departments, schools, and facilities. An evaluation with benchmarks is required, and $10 million is authorized annually for fiscal years 2027–2031.
- Definition: "Bleeding disorder" covers inheritable conditions impairing blood clotting, such as hemophilia, von Willebrand disease, and rare factor deficiencies.
Significant Changes to Existing Law The bill introduces new federal requirements for interagency review and a public education campaign but does not amend or repeal any existing statutes. It establishes fresh mandates for HHS coordination and grant funding.
Potential Impacts
- Government Agencies: Requires HHS to lead reviews and coordinate with multiple federal entities, potentially increasing administrative workload and interagency collaboration.
- Citizens: Could improve diagnosis, treatment access, and awareness for women and girls with bleeding disorders, especially in underserved areas, with possible reductions in adverse pregnancy outcomes and unnecessary procedures.
- International Relations: No direct effects identified in the legislation.
- Other: May support military-related blood research indirectly through enhanced scientific understanding.
Main Stakeholders Affected
- Women and girls living with bleeding disorders, particularly those in rural or underserved areas.
- Healthcare providers, including those at hemophilia treatment centers, primary care physicians, and specialists.
- Federal agencies involved in health research and services.
- National bleeding disorders patient and provider advocacy organizations.
- Entities receiving federal research grants on bleeding disorders.
- Public health departments, schools, and medical training institutions.
Notable Legal, Constitutional, or Political Implications The bill operates within existing HHS authority and does not raise apparent constitutional issues. It emphasizes public comment processes and evidence-based approaches but introduces no new regulatory powers or enforcement mechanisms beyond grant administration and reporting.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (3)
Rep. Wilson, Joe [R-SC-2], Rep. McBride, Sarah [D-DE-At Large], Del. Norton, Eleanor Holmes [D-DC-At Large]
Recent Actions
- 2026-05-13: Referred to the House Committee on Energy and Commerce.
- 2026-05-13: Introduced in House
- 2026-05-13: Introduced in House
Bill Versions
- Fostering Effective Diagnosis and Treatment for Underserved Populations with Bleeding Disorders Act of 2026 — issued 2026-05-13 — PDF (8 pages)